Giant cell myocarditis after first dose of BNT162b2 – a case report

Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirsch, Valentin G., Schallhorn, Sven, Zwadlo, Carolin, Diekmann, Johanna, Länger, Florian, Jonigk, Danny David, Kempf, Tibor, Schultheiss, Heinz‐Peter, Bauersachs, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350328/
https://www.ncbi.nlm.nih.gov/pubmed/35733299
http://dx.doi.org/10.1002/ejhf.2590
Descripción
Sumario:Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work‐up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context of myocarditis after mRNA vaccination we discuss this rare aetiology and the patient's treatment strategy in the light of current recommendations.

Ejemplares similares